A 340B View of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan): Financial Misalignment in Radioligand Therapy
Practical Radiation Oncology · 2026-05
DOI: 10.1016/j.prro.2026.05.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practical Radiation Oncology, 2026-05. Verfasst von Adam Katzenberg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania. Electroni…. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: Adam.Katzenberg@jefferson.edu.
- Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.
Zitieren
APA
Katzenberg, A., DiNome, J., Beecher, R., & Den, R. (2026). A 340B View of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan): Financial Misalignment in Radioligand Therapy. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2026.05.001
Vancouver
Katzenberg A, DiNome J, Beecher R, Den R. A 340B View of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan): Financial Misalignment in Radioligand Therapy. Practical Radiation Oncology. 2026. doi:10.1016/j.prro.2026.05.001
BibTeX
@article{Katzenberg2026,
author = {Katzenberg, Adam and DiNome, Jessie and Beecher, Robert and Den, Robert},
title = {A 340B View of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan): Financial Misalignment in Radioligand Therapy},
journal = {Practical Radiation Oncology},
year = {2026},
doi = {10.1016/j.prro.2026.05.001}
}
EUVIMED